1-[(1-naphthalenyl)sulfonyl]-2,4-imidazolidinedione | 111261-87-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[(1-naphthalenyl)sulfonyl]-2,4-imidazolidinedione
• 英文别名: 1-(Naphthalene-1-sulfonyl)imidazolidine-2,4-dione；1-naphthalen-1-ylsulfonylimidazolidine-2,4-dione
• CAS: 111261-87-1
• 化学式: C₁₃H₁₀N₂O₄S
• 分子量: 290.299
• InChiKey: XXBCGNGNWXBWNF-UHFFFAOYSA-N

物化性质

• 密度：
  1.526±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  91.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-萘磺酰氯 在 吡啶 、 水 、 乙酸酐 、 sodium carbonate 、 氯乙酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 27.5h， 生成 1-[(1-naphthalenyl)sulfonyl]-2,4-imidazolidinedione
  参考文献：
  名称：

  Naphthalenylsulfonyl-hydantoins as aldose reductase inhibitors

  摘要：

  Accumulation of intracellular sorbitol, formed from glucose by aldose reductase, is believed to play an important role in the development of certain chronic complications of diabetes mellitus. Several 1-(naphthalenylsulfonyl)hydantoins inhibit aldose reductase isolated from bovine lens in vitro, and decrease galactitol formation in sciatic nerves of galactosemic rats in vivo. The 5-bromo analogue (entry 12, table I) was found to be the most orally active aldose reductase inhibitor of this series with an ED50 value of 8.1 mg/kg po. The 1-(naphthalenylsulfonyl)-2-thiohydantoin analogues with the exception of entry 11 (table I) which showed good in vivo activity, were either inactive or had only marginal activity.

  DOI：

  10.1016/0223-5234(91)90096-6

文献信息

• Naphthalenylsulfonylimidazolidinediones and their thioxo analogs
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0251784A2

  公开（公告）日：1988-01-07

  The invention comprises naphthalenylsulfonylimidazolidinediones of formula (I) wherein R⁴, R⁵, R⁶ and R⁷ are hydrogen, halogen, trifluoromethyl, methoxy or dimethylamino and X is oxygen or sulfur and the pharmaceutically acceptable salts thereof, and methods for their preparation. The compounds are new aldose reductase inhibitors useful for the treatment or prevention of diabetic complications. Pharmaceutical compositions containing the compounds and methods for manufacturing same are also included in the invention.

  本发明包括式 (I) 的萘基磺酰亚胺唑烷二酮，其中 R⁴、R⁵、R⁶ 和 R⁷ 是氢、卤素、三氟甲基、甲氧基或二甲基氨基，X 是氧或硫及其药学上可接受的盐，以及它们的制备方法。 这些化合物是新型醛糖还原酶抑制剂，可用于治疗或预防糖尿病并发症。 本发明还包括含有这些化合物的药物组合物及其生产方法。
• Hydantoin derivatives
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0355827A2

  公开（公告）日：1990-02-28

  The present invention relates to hydantoin derivatives, represented by the formula (I): and non-toxic salts, solvates and solvates of non-toxic salts thereof; wherein q represents a mono- or a fused heterocyclic group which may be substituted by one or more substituents which are same or different and selected from a group consisting of a halogen atom, an alkyl group, a nitro group, a cyano group, an optionally protected carboxy group, an optionally protected carboxymethyl group, a halogenated alkyl group, an alkylthio group, an alkylcarbonyl group, an alkoxy group, an alkylsulfinyl group, an alkylsulfonyl group, an optionally protected hydroxy group, an optionally protected amino group, a carbamoyl group and a phenyl group, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and intermediate compounds in the synthesis of said hydantoin derivatives.

  本发明涉及由式(I)表示的海因衍生物： 及其无毒盐、溶剂和无毒盐的溶剂；其中 q 代表可被一个或多个相同或不同的取代基取代的单杂环基团或融合杂环基团，这些取代基团选自卤素原子、烷基、硝基、氰基、受任选保护的羧基、受任选保护的羧甲基、卤代烷基、烷硫基、烷基羰基、烷氧基烷基亚磺酰基、烷基磺酰基、任选受保护的羟基、任选受保护的氨基、氨基甲酰基和苯基，生产所述海因衍生物的工艺，含有至少一种所述海因衍生物作为醛糖还原酶抑制剂的药物组合物，以及合成所述海因衍生物的中间化合物。
• OKUDA, DZYUN;SAIVA, KADZUTOMO;INAGAKI, KADZUXIRO;XIRANO, EHKIDZI
  作者：OKUDA, DZYUN、SAIVA, KADZUTOMO、INAGAKI, KADZUXIRO、XIRANO, EHKIDZI

  DOI：——

  日期：——
• Hydantoin derivatives, process for their preparation and pharmaceutical compositions containing the same as well as their use
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0305947B1

  公开（公告）日：1992-07-29
• Hydantoin derivatives for use as hypoglycemic and/or hypolipidemic agents
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0444546B1

  公开（公告）日：1996-09-11